BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has completed the third installment of its private placement, raising $305,000 by issuing 6.1 million units at $0.05 each, to support its business plans following the acquisition of a portfolio of immunological assets. CEO James Passin personally invested $300,000 in this round, indicating strong insider confidence.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
